New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2013
09:25 EDTNBIX, NBIX, NBIXPiper Jaffray's biotech research team holds analyst/industry conference call
Analyst Research Team, along with Dr. Joseph Jankovic, Professor of Neurology at Baylor College of Medicine, discusses current therapies and the role of selective VMAT-2 inhibitors for tardive dyskinesia and other movement disorders, along with Neurocrine's NBI-98854, on an Analyst/Industry conference call to be held on April 5 at 10 am.
News For NBIX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 10, 2016
16:43 EDTNBIXOn The Fly: Top stock stories for Wednesday
Stocks endured another roller coaster session as Fed Chair Yellen kicked off her annual pilgrimage to Capitol Hill. The averages began the day in positive territory, helped by an early rise in oil prices. The averages shot higher following a bullish oil inventory report, but soon afterward reversed and began to lose ground. The Nasdaq, which had been the strongest of the indexes throughout the day, maintained its leadership while the other indexes faltered. The Dow struggled under the weight of Disney (DIS) shares, which were lower following the company's earnings report, and gave in to the selling pressure for good late in the day, falling into the red near the close of the session. ECONOMIC EVENTS: In the U.S., Federal Reserve Chair Janet Yellen testified before the House Financial Services Committee. Tomorrow, she will present to the Senate Banking Committee. In her prepared remarks ahead of her testimony, Yellen said U.S. financial conditions have recently become "less supportive of growth," citing declines in the stock market, higher borrowing rates for riskier borrowers, and further appreciation of the dollar. Yellen also noted that foreign economic developments pose risks to domestic economic growth, noting that these growth concerns, along with strong supply conditions and high inventories, contributed to the recent fall in the prices of oil and other commodities. In a Q&A session, Yellen said she did not think recent market volatility warrants a rate cut. Separately, the Treasury announced a $55.2B budget surplus for January, much improved from the $17.5B shortfall registered in January of 2015. In Asia, Japanese stock indexes sank further, with the Topix falling another 3% and the Nikkei dropping over 2%. COMPANY NEWS: Continuing a recent trend in the media space, Time Warner (TWX) reported lower than expected quarterly revenues and saw its stock punished. The shares ended the day down 5% to $60.03, after slipping much further early in the session, despite the fact that its fourth quarter earnings topped expectations, as did its profit forecast for the new fiscal year, with the company also hiking its dividend 15% and authorizing a $5B share buyback program. Meanwhile, Disney last night reported better than expected earnings and revenue, powered by its blockbuster "Star Wars" film, but its shares fell 3.8% to $88.82 as investors continue to worry about the future of traditional media companies in the face of industry shifting trends such as cord-cutting and over-the-top video... SolarCity (SCTY) plunged 29.3% to $18.63 after reporting lower than projected installations in Q4 and giving lower than expected Q1 installation guidance. The stock's slide also weighed on its peers in the solar space, as First Solar (FSLR) fell 3% and Sunrun (RUN) dropped 15.7%. MAJOR MOVERS: Among the noteworthy gainers was Fitbit (FIT), which advanced 2.7% to $14.68 after Vanguard reported a 9.2% stake in the company and Salesforce (CRM) founder, chairman, and CEO Marc Benioff reported a 5% stake. Also higher was Neurocrine Biosciences (NBIX), which rose 4.7% to $33.70 after AbbVie (ABBV), in cooperation with the company, announced that the second Phase 3 trial of endometriosis drug Elagolix met its co-primary endpoints. Meanwhile, Akamai (AKAM) and Panera Bread (PNRA) gained 21.2% and 4.95%, respectively, after reporting quarterly results. Among the notable losers was Retrophin (RTRX), which declined 0.7% to $13.64 after Imprimis Pharmaceuticals (IMMY) said it intends to make an alternative to the company's Thiola product. Also lower were ARM Holdings (ARMH) and Demandware (DWRE), which lost 8.82% and 8.81%, respectively, after reporting quarterly results. INDEXES: The Dow fell 99.64, or 0.62%, to 15,914.74, the Nasdaq gained 14.83, or 0.35%, to 4,283.59, and the S&P 500 slipped 0.35, or 0.02%, to 1,851.86.
06:58 EDTNBIXAbbVie reports second Elagolix Phase 3 clinical trial met co-primary endpoint
AbbVie (ABBV), in cooperation with Neurocrine Biosciences (NBIX), announced positive top-line results from the second of two replicate pivotal Phase 3 clinical trials evaluating the efficacy and safety of Elagolix in premenopausal women who suffer pain from endometriosis. Trial results show that after six months of continuous treatment, both doses of Elagolix met the study's co-primary endpoints. Elagolix reduced scores of menstrual pain and non-menstrual pelvic pain, or NMPP, associated with endometriosis, at month three and month six, as measured by the Daily Assessment of Endometriosis Pain scale. Responder rates for the co-primary endpoints from this second Phase 3 pivotal study are consistent with results from the first Phase 3 pivotal study.
February 2, 2016
08:59 EDTNBIXLeerink views doc checks as positive for ACADIA, Neurocrine
Subscribe for More Information
08:35 EDTNBIXNeurocrine begins Phase II clinical trial for NBI-98854
Subscribe for More Information
January 28, 2016
07:12 EDTNBIXAbbVie intiates enrollment in Phase 3 clinical program for Elagolix
AbbVie (ABBV), in cooperation with Neurocrine Biosciences (NBIX), announced the initiation of the first of two planned Phase 3 clinical studies evaluating the safety and efficacy of Elagolix alone or in combination with add-back therapy compared to placebo. These studies are designed to assess the change in menstrual blood loss utilizing the alkaline hematin method, comparing baseline to month six of treatment. Additional secondary efficacy endpoints are being evaluated; including assessing changes in fibroid volume, monthly blood loss and hemoglobin levels. Bone mineral density will also be assessed.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use